Initial severity of depression and efficacy of cognitive-behavioural therapy: Individual-participant data meta-analysis of pill-placebo-controlled trials

British Journal of Psychiatry

Volumn 210, Issue 3, 2017, Pages 190-196

  Furukawa, Toshi A ^a   Weitz, Erica S ^b   Tanaka, Shiro ^a   Hollon, Steven D ^c   Hofmann, Stefan G ^d   Andersson, Gerhard ^e,f   Twisk, Jos ^b   De Rubeis, Robert J ^g   Dimidjian, Sonas ^h   Hegerl, Ulrich ⁱ   Mergl, Roland ⁱ   Jarrett, Robin B ^j   Vittengl, Jeffrey R ^k   Watanabe, Norio ^a   Cuijpers, Pim ^b  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c VANDERBILT UNIVERSITY   (United States)

^d BOSTON UNIVERSITY   (United States)

^e LINKÖPING UNIVERSITY   (Sweden)

^f KAROLINSKA INSTITUTE   (Sweden)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF COLORADO   (United States)

ⁱ UNIVERSITY OF LEIPZIG   (Germany)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k TRUMAN STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; COGNITIVE BEHAVIORAL THERAPY; DISEASE SEVERITY; EMBASE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; MEDLINE; META ANALYSIS; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; COGNITIVE THERAPY; DEPRESSIVE DISORDER, MAJOR; OUTCOME ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

COGNITIVE THERAPY; DEPRESSIVE DISORDER, MAJOR; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 85018754359     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.116.187773     Document Type: Review

References (39)

1. National Institute for Health and Care Excellence. Depression: The Treatment and Management of Depression in Adults (partial update of NICE clinical guideline 23). NICE, 2009.
2. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (third edition). Am J Psychiatry 2010; 167 (suppl): 1-152.
3. Cuijpers P, Turner EH, Mohr D.C., Hofmann SG, Andersson G, Berking M, et al Comparison of psychotherapies for adult depression to pill placebo control groups: a meta-analysis. Psychol Med 2013: 1-11.
4. Driessen E, Cuijpers P, Hollon S.D., Dekker JJ. Does pretreatment severity moderate the efficacy of psychological treatment of adult outpatient depression? A meta-analysis. J Consult Clin Psychol 2010; 78: 668-80.
5. Simmonds MC, Higgins JP Covariate heterogeneity in meta-analysis: criteria for deciding between meta-regression and individual patient data. Stat Med 2007; 26: 2982-99.
6. Bower P, Kontopantelis E, Sutton A., Kendrick T, Richards DA, Gilbody S, et al Influence of initial severity of depression on effectiveness of low intensity interventions: meta-analysis of individual patient data. BMJ 2013; 346: f540.
7. Chen P, Furukawa TA, Shinohara K, Honyashiki M., Imai H, Ichikawa K, et al Quantity and quality of psychotherapy trials for depression in the past five decades. J Affect Disord 2014; 165: 190-5.
8. Barth J, Munder T, Gerger H., Nuesch E, Trelle S, Znoj H., et al. Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. PLoS Med 2013; 10: e1001454.
9. Cuijpers P, Smit F, Bohlmeijer E., Hollon SD, Andersson G. Efficacy of cognitive-behavioural therapy and other psychological treatments for adult depression: meta-analytic study of publication bias. Br J Psychiatry 2010; 196: 173-8.
10. Furukawa TA, Noma H, Caldwell D.M., Honyashiki M., Shinohara K, Imai H, et al Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis. Acta Psychiatr Scand 2014; 130: 181-92.
11. Cuijpers P, van Straten A, Andersson G, van Oppen P. Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. J Consult Clin Psychol 2008; 76: 909-22.
12. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
13. DeRubeis RJ, Hollon SD, Amsterdam J.D., Shelton RC, Young PR, Salomon RM, et al Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005; 62: 409-16.
14. Dimidjian S, Hollon SD, Dobson K.S., Schmaling KB, Kohlenberg RJ, Addis ME, et al Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol 2006; 74: 658-70.
15. Beck AT, Ward CH, Mendelson M, Mock J., Erbaugh J. An inventory for measuring depression. Arch Gen Psych 1961; 4: 561-71.
16. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson S.S., Farrar JT, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012; 367: 1355-60.
17. National Research Council. The Prevention and Treatment of Missing Data in Clinical Trials. National Academies Press, 2010.
18. Stewart LA, Clarke M, Rovers M., Riley RD, Simmonds M, Stewart G, et al Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD Statement. JAMA 2015; 313: 1657-65.
19. Elkin I, Shea MT, Watkins J.T., Imber SD, Sotsky SM, Collins JF, et al National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry 1989; 46: 971-82.
20. Jarrett RB, Schaffer M, McIntire D., Witt-Browder A, Kraft D, Risser RC Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999; 56: 431-7.
21. Hegerl U, Hautzinger M, Mergl R., Kohnen R, Schutze M, Scheunemann W., et al. Effects of pharmacotherapy and psychotherapy in depressed primary-care patients: a randomized, controlled trial including a patients' choice arm. Int J Neuropsychopharmacol 2010; 13: 31-44.
22. Cuijpers P, Turner EH, Mohr D.C., Hofmann SG, Andersson G, Berking M, et al Comparison of psychotherapies for adult depression to pill placebo control groups: a meta-analysis. Psychol Med 2014; 44: 685-95.
23. Cunningham JA, Kypri K, McCambridge J. Exploratory randomized controlled trial evaluating the impact of a waiting list control design. BMC Med Res Methodol 2013; 13: 150.
24. Fawcett J, Epstein P, Fiester S.J., Elkin I., Autry JH. Clinical management-imipramine/placebo administration manual. NIMH Treatment of Depression Collaborative Research Program. Psychopharmacol Bull 1987; 23: 309-24.
25. Butler AC, Chapman JE, Forman E.M., Beck AT. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev 2006; 26: 17-31.
26. Cuijpers P, van Straten A, Bohlmeijer E, Hollon S.D., Andersson G. The effects of psychotherapy for adult depression are overestimated: a meta-analysis of study quality and effect size. Psychol Med 2010; 40: 211-23.
27. Lynch D, Laws KR, McKenna PJ Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials. Psychol Med 2010; 40: 9-24.
28. Stewart LA, Tierney JF To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 2002; 25: 76-97.
29. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010; 340: c221.
30. Turner EH, Matthews AM, Linardatos E, Tell R.A., Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252-60.
31. Amick HR, Gartlehner G, Gaynes B.N., Forneris C., Asher GN, Morgan LC, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ 2015; 351: h6019.
32. Weitz ES, Hollon SD, Twisk J, van Straten A, Huibers MJ, David D, et al Baseline depression severity as moderator of depression outcomes between cognitive behavioral therapy vs pharmacotherapy: an individual patient data meta-analysis. JAMA Psychiatry 2015; 72: 1102-9.
33. Fournier JC, DeRubeis RJ, Hollon S.D., Dimidjian S., Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303: 47-53.
34. Furukawa TA, Levine SZ, Tanaka S, Goldberg Y., Samara M, Davis JM, et al Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry 2015; 72: 14-21.
35. Gibbons RD, Hur K, Brown C.H., Davis JM, Mann JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; 69: 572-9.
36. Gartlehner G, Hansen RA, Morgan L.C., Thaler K., Lux L, Van Noord M, et al. Comparative benfits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med 2011; 155: 772-85.
37. Ioannidis JP, Karassa FB The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence. BMJ 2010; 341: c4875.
38. Institute of Medicine Committee on Strategies for Responsible Sharing of Clinical Trial Data. Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risks. National Academic Press, 2015.
39. Furukawa TA. From effect size into number needed to treat. Lancet 1999; 353: 1680.